Abstract Library

#4248 Tryptophan pathway metabolites as prognostic biomarkers of recurrent disease in curatively operated neuroendocrine tumor patients

Introduction: The majority of NET patients experience recurrent disease after curative surgery. There is a need for prognostic biomarkers in this patient group.

Conference:

Presenting Author: Johansen S

Authors: Johansen S, Hansen T, Goll R, Florholmen J,

Keywords: Plasma Tryptophan Metabolites, Prognostic Biomarker, Recurrent Disease after Curative Surgery,

#3820 Metabolites in the tryptophan pathway as a diagnostic tool in neuroendocrine tumor patients

Introduction: A good and accessible biomarker is of great value in neuroendocrine tumor (NET) patients, especially considering its frequently indolent nature and long-term follow up.

Conference:

Presenting Author:

Authors: Johansen S, Hansen T, Meyer R, Jensen E, Goll R,

Keywords: serotonin, tryptophan pathway, LC-MS/MS, NEUROENDOCRINE TUMOR,

#3251 Impact of Wnt signalling on CXCR4 expression and function

Introduction: Loss of Somatostatin Receptor 2 (SSTR2) expression and rising Chemokine Receptor Type 4 (CXCR4) expression are associated with increasing dedifferentiation in Neuroendocrine Tumors (NET). CXCR4 expression is associated with enhanced metastatic and invasive potential and worse prognosis in NET, but might be a theranostic target in NET not sufficiently expressing SSTR2. Likewise, aberrant activation of Wnt/β-catenin signalling may promote a more aggressive phenotype in NET.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Weich A

Authors: Weich A, Rogoll D, Mayer L, Meining A, Kudlich T,

Keywords: neuroendocrine, NET, CXCR4, Wnt, Wnt Signalling, beta-catenin, BON-1, QGP-1,

#3242 Establishment and characterization of a new neuroendocrine carcinoma cell model

Introduction: The development of treatment strategies for neuroendocrine carcinomas (NEC) requires in vitro models expressing NEC–specific targets. The CXC Chemokine Receptor Type 4 (CXCR4), that is expressed in NEC with decreasing differentiation, as well as factors involved in chemotherapy resistance may represent such targets.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Weich A

Authors: Weich A, Schreiner J, Rogoll D, Werner R, Meining A,

Keywords: neuroendocrine, net, CXCR4, Wnt signalling, beta-catenin, BON-1, QGP-1,

#3222 Impact of Wnt signalling on somatostatin receptor (SSTR) expression and function

Introduction: Somatostatin receptors (SSTR) are expressed by most differentiated neuroendocrine tumors (NET) and are important treatment targets. Loss of SSTR expression is associated with a worse prognosis. Deregulation of Wnt/β-catenin signalling has been demonstrated in NET. Treatment with the Wnt inhibitor 5-aza-2'-deoxycytidine (5-aza-CdR) led to growth inhibition in a NET tumor cell line. Other data show an increase in SSTR2 mRNA expression and cellular uptake of radiolabelled octreotide in NET cell lines after incubation with 5-aza-CdR.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Weich A

Authors: Weich A, Rogoll D, Mayer L, Peschka M, Meining A,

Keywords: NET, Wnt Signalling, somatostatin receptor, BON-1, QGP-1, SSTR,